FDA Commissioner Controversy Delays “Behind-The-Counter” Rx Precedent
FDA appears to be ready to create a new class of "behind the counter" OTC drugs
You may also be interested in...
Acting FDA Commissioner Lester Crawford's prospects for Senate confirmation appear to be in jeopardy after the Health Committee disclosed concerns about a conduct allegation lodged against the nominee
Senate Health Committee Democrats are threatening to delay the confirmation of Lester Crawford as commissioner until the agency makes a decision about Barr's application to switch the emergency contraceptive Plan B to OTC status
Senate Health Committee Democrats are asking to meet with FDA Commissioner nominee Lester Crawford to discuss the Rx-to-OTC switch of emergency contraceptive Plan B prior to voting on his confirmation